A Phase 0 Imaging Trial of [203Pb]Pb-VMT-α-NET to Enable Dosimetry and Treatment Planning for Refractory or Relapsed Metastatic Neuroendocrine Tumors with [212Pb]Pb-VMT-α-NET.

Overview of attention for article published in Journal of Nuclear Medicine, February 2026

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)

Mentioned by

news: 2 news outlets

Readers on

mendeley: 3 Mendeley

So far, Altmetric has seen 3 news stories from 2 outlets.

The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: February 13, 2026

EurekAlert!, 13 Feb 2026

Reston, VA (February 13, 2026)New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM).

Nuclear Medicine Journal Preview: Feb 6, 2026

Mirage News, 06 Feb 2026

Reston, VA (February 6, 2026)—New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM).

The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: February 6, 2026

EurekAlert!, 06 Feb 2026

Reston, VA (February 6, 2026)—New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM).

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.